Manling Luo1, Yuanqiao He2, Baogang Xie3, Shiyun Li1, Fuqiang Gan1, Shouhua Zhang4, Puying Luo5. 1. Department of Obstetrics and Gynecology, The Affiliated People's Hospital of Nanchang University, Jiangxi Provincial People's Hospital, Nanchang University School of Medicine, Nanchang City, Jiangxi Province, China. 2. Department of Jiangxi Province Key Laboratory of Laboratory Animal, Laboratory Animal Science Center of Nanchang University, Nanchang Royo Biotechnology Co., Ltd, Nanchang City, Jiangxi Province, China. 3. Department of Pharmaceutics, Medical College of Jiaxing University, Jiaxing, China. 4. Department of Pediatric Surgery, Jiangxi Children's Hospital, Nanchang City, Jiangxi Province, China. zshouhua416@163.com. 5. Department of Obstetrics and Gynecology, The Affiliated People's Hospital of Nanchang University, Jiangxi Provincial People's Hospital, Nanchang University School of Medicine, Nanchang City, Jiangxi Province, China. luopuying1979@126.com.
Abstract
OBJECTIVE: The lack of appropriate preclinical models of ovarian yolk sac tumor (OYST) is currently hindering the pursuit of new methods of treatment and investigation of the pathogenesis of the disease. We developed and characterized an OYST patient-derived xenograft (PDX) model in this study. METHODS: Tumor fragments from a patient with an OYST were implanted subcutaneously into BALB/c Nude mice. Engrafted xenografts were compared with the original tumor according to histology, immunohistochemistry, humanized identified, and drug efficacy testing with in vivo treatment programs. RESULTS: There was a high degree of histologic and immunohistochemical (IHC) resemblance between the established PDX model and its corresponding human tumors. Bleomycin, etoposide, and cisplatin (JEB) chemotherapy regimens were effective in clinical patients and were effective in the OYST PDX model; therefore, the effect of PDX intervention was consistent with clinical outcomes of OYSTs. CONCLUSION: We have successfully established an OYST PDX model. This OYST model preserves the basic molecular features of the primary human tumor, thereby providing a valuable method to preclinically evaluate new treatments and explore disease pathogenesis.
OBJECTIVE: The lack of appropriate preclinical models of ovarian yolk sac tumor (OYST) is currently hindering the pursuit of new methods of treatment and investigation of the pathogenesis of the disease. We developed and characterized an OYST patient-derived xenograft (PDX) model in this study. METHODS:Tumor fragments from a patient with an OYST were implanted subcutaneously into BALB/c Nude mice. Engrafted xenografts were compared with the original tumor according to histology, immunohistochemistry, humanized identified, and drug efficacy testing with in vivo treatment programs. RESULTS: There was a high degree of histologic and immunohistochemical (IHC) resemblance between the established PDX model and its corresponding humantumors. Bleomycin, etoposide, and cisplatin (JEB) chemotherapy regimens were effective in clinical patients and were effective in the OYST PDX model; therefore, the effect of PDX intervention was consistent with clinical outcomes of OYSTs. CONCLUSION: We have successfully established an OYST PDX model. This OYST model preserves the basic molecular features of the primary humantumor, thereby providing a valuable method to preclinically evaluate new treatments and explore disease pathogenesis.
Authors: Joyce F Liu; Sangeetha Palakurthi; Qing Zeng; Shan Zhou; Elena Ivanova; Wei Huang; Ioannis K Zervantonakis; Laura M Selfors; Yiping Shen; Colin C Pritchard; Mei Zheng; Vilmos Adleff; Eniko Papp; Huiying Piao; Marian Novak; Susan Fotheringham; Gerburg M Wulf; Jessie English; Paul T Kirschmeier; Victor E Velculescu; Cloud Paweletz; Gordon B Mills; David M Livingston; Joan S Brugge; Ursula A Matulonis; Ronny Drapkin Journal: Clin Cancer Res Date: 2016-08-29 Impact factor: 12.531
Authors: Jody E Hooper; Emma L Cantor; Macgregor S Ehlen; Avirup Banerjee; Suman Malempati; Peter Stenzel; Randy L Woltjer; Regina Gandour-Edwards; Neal C Goodwin; Yan Yang; Pali Kaur; Carol J Bult; Susan D Airhart; Charles Keller Journal: Sarcoma Date: 2015-11-30
Authors: C Newton; K Murali; A Ahmad; H Hockings; R Graham; V Liberale; S-J Sarker; J Ledermann; D M Berney; J Shamash; S Banerjee; S Stoneham; M Lockley Journal: Eur J Cancer Date: 2019-04-04 Impact factor: 9.162
Authors: Zachary C Dobbin; Ashwini A Katre; Adam D Steg; Britt K Erickson; Monjri M Shah; Ronald D Alvarez; Michael G Conner; David Schneider; Dongquan Chen; Charles N Landen Journal: Oncotarget Date: 2014-09-30